Second Quarter 2026
Filed Aug 11, 2026Mineralys Therapeutics reports second-quarter 2026 net loss of $241.1 million, completes financing initiatives, and maintains a December 22, 2026 PDUFA target date for lorundrostat.
The company strengthened liquidity and advanced launch readiness ahead of the December 22, 2026 PDUFA target date, but reported a substantially larger net loss driven primarily by the $200.0 million upfront payment to Tanabe and higher commercial-build expenses.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $221.4 million | – | – |
| General and administrative expensesGAAP | $24.7 million | – | – |
| Total other income, netGAAP | $5.0 million | – | – |
| Net lossGAAP | $241.1 million | – | – |
| Cash, cash equivalents and investmentsother | $661.4 million | – | – |
PDUFA target date of December 22, 2026 outlook
- NoteThe Company continues to advance commercial launch preparations ahead of lorundrostat’s PDUFA target date of December 22, 2026 and remains on track.
- NoteThe Company expects to have the sales organization established in advance of the anticipated PDUFA target date.
- NoteThe Company believes that its current cash, cash equivalents and investments will be sufficient to fund planned operations, including the commercial launch of lorundrostat, into 2028.
What drove it
- The increase in R&D expenses was primarily due to the $200.0 million upfront payment to Tanabe in June 2026 in connection with the license agreement amendment.
- R&D expense also reflected $0.6 million of increased personnel-related expenses and $0.2 million of increased clinical supply, manufacturing, regulatory and other costs.
- R&D expense increases were partially offset by $17.8 million of lower preclinical and clinical costs, primarily due to the conclusion of the lorundrostat pivotal program in the second quarter of 2025.
- The increase in G&A expenses was primarily due to $8.0 million in higher professional fees and $8.0 million of increased personnel-related expenses resulting from headcount growth and increased compensation.
- Total other income, net increased primarily due to $2.3 million of increased interest earned on investments as a result of higher average cash balances, partially offset by $0.8 million of interest and amortization expense related to the senior secured term loan.
- The Company stated that an experienced commercial leadership team is in place, initial sales territories and priority geographies have been identified, and payer engagement continues.
Concerns
- Lorundrostat remains investigational and the NDA remains under FDA review, with a PDUFA target date of December 22, 2026.
- The $200.0 million Tanabe upfront payment was the primary driver of the higher R&D expense and net loss.
- The Company has remaining Tanabe commercial milestone obligations of up to $255.0 million in the aggregate, plus up to $10.0 million related to commercialization for a potential second indication.
- G&A expenses increased to support headcount, compensation, professional fees and other administrative activities ahead of a potential commercial launch.
- The senior secured term loan produced $0.8 million of interest and amortization expense during the quarter.
What to watch
- FDA review of the lorundrostat NDA and the PDUFA target date of December 22, 2026.
- Progress in establishing the sales organization in advance of the anticipated PDUFA target date.
- Additional long-term safety and efficacy data from the ongoing Transform-HTN open-label extension trial.
- Potential availability of additional tranches under the senior secured term loan facility.
- Completion of the amended Tanabe arrangement, including the subsequent assignment to Mineralys of Tanabe’s rights in the licensed intellectual property.
Balance sheet and cash flow
- Cash, cash equivalents and investments were $661.4 million as of June 30, 2026, compared to $656.6 million as of December 31, 2025.
- Completed a follow-on public offering of 5,660,378 shares of common stock, generating gross proceeds of approximately $150.0 million.
- Entered into a senior secured term loan facility for up to $500.0 million from funds managed by Pharmakon Advisors, LP, including an initial $100.0 million tranche drawn in June 2026.
- The Company made an upfront cash payment to Tanabe of $200.0 million and agreed to pay additional commercial milestone payments of up to $100.0 million in the aggregate.
- The Company has remaining obligations to pay Tanabe commercial milestone payments, including the New Milestones, of up to $255.0 million in the aggregate upon first commercial sale and upon meeting certain annual sales targets, as well as up to $10.0 million related to commercialization for a potential second indication.
Analysis
Mineralys remains a pre-commercial biopharmaceutical company preparing for a potential lorundrostat launch rather than reporting product revenue. The principal near-term operating catalyst is the FDA review of its NDA for lorundrostat in hypertension in combination with other antihypertensive drugs, with a PDUFA target date of December 22, 2026. Management said commercial preparations remain on track, with commercial leadership in place, sales territories and priority geographies identified, and payer engagement underway.
Second-quarter expense growth was dominated by the strategic Tanabe license amendment. R&D expense was $221.4 million, compared with $38.3 million in the prior-year quarter, primarily because of the $200.0 million upfront payment. The company also cited higher personnel-related expense and clinical supply, manufacturing, regulatory and other costs, partially offset by lower preclinical and clinical costs following the conclusion of the lorundrostat pivotal program in the second quarter of 2025. G&A expense was $24.7 million, compared with $8.5 million, led by professional fees and personnel-related expense associated with headcount growth and compensation.
The expense profile resulted in a GAAP net loss of $241.1 million, compared with $43.3 million in the prior-year quarter. Total other income, net was $5.0 million, compared with $3.5 million, as higher investment interest income was partly offset by interest and amortization expense on the term loan entered into during June 2026. No revenue, gross margin, operating income or loss, or EPS was provided in the supplied filing text.
Financing activity materially reshaped the balance sheet and lorundrostat economics. Mineralys completed a follow-on offering that generated gross proceeds of approximately $150.0 million and drew an initial $100.0 million tranche under a facility of up to $500.0 million. Cash, cash equivalents and investments were $661.4 million as of June 30, 2026, compared with $656.6 million as of December 31, 2025. Management stated that current cash, cash equivalents and investments should fund planned operations, including a commercial launch, into 2028.
The Tanabe amendment eliminated royalty obligations but replaced them with substantial upfront and contingent payments. Beyond the $200.0 million upfront payment, Mineralys agreed to additional commercial milestone payments of up to $100.0 million and disclosed remaining commercial milestone obligations of up to $255.0 million in the aggregate, plus up to $10.0 million for commercialization of a potential second indication. The central items to monitor are the FDA decision, execution of commercial buildout, results from the open-label extension, access to additional debt tranches, and finalization of the Tanabe intellectual-property rights transfer.
Management, verbatim
Mineralys is advancing toward an exciting next chapter as we prepare for the commercial launch of lorundrostat, pending FDA approval. The efficacy and safety profile of lorundrostat supports its potential as a compelling treatment option for patients with uncontrolled or resistant hypertension.
Jon Congleton, Chief Executive Officer of Mineralys
I am very pleased to join the team at Mineralys in advance of the December PDUFA target date. Uncontrolled or resistant hypertension is a major driver of cardiovascular morbidity and mortality and a continuing issue for millions of Americans. I look forward to helping bring new treatment options, like lorundrostat, to patients with hypertension and other conditions where modulating dysregulated aldosterone may provide significant benefit.
Dr. Terry Ferguson, Chief Medical Officer of Mineralys
Not in the filing
stated, not guessed- Total revenue was not reported in the supplied filing text.
- Segment revenue was not reported in the supplied filing text.
- Gross margin was not reported in the supplied filing text.
- Operating income or loss was not reported in the supplied filing text.
- GAAP diluted EPS was not reported in the supplied filing text.
- Non-GAAP financial metrics, including non-GAAP net income or loss and non-GAAP EPS, were not reported in the supplied filing text.
- Operating cash flow was not reported in the supplied filing text.
- Free cash flow was not reported in the supplied filing text.
- Share repurchases and dividends were not reported in the supplied filing text.
- Prior-quarter figures for R&D expense, G&A expense, total other income, net, and net loss were not reported in the supplied filing text.
- Year-over-year and quarter-over-quarter percentage changes for reported financial metrics were not reported in the supplied filing text.
- No previous-quarter outlook was provided.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.